Technology created at NCATS and refined by a Center-supported small business has enabled re-use of plastic plates for high-throughput screening.
NCATS and National Institute of Diabetes and Digestive and Kidney Diseases researchers found that a drug used to treat allergy symptoms also limited hepatitis C virus activity in mice.
NCATS support to Yale team leads to expedited clinical trial to test experimental drug as Alzheimer's treatment.
Researchers tested the cells of more than 1,000 individuals with different genetic backgrounds for sensitivity to 179 therapeutic and industrial chemical compounds.
A financial analysis in Science Translational Medicine finds that two NCATS rare diseases programs have led to reduced cost of developing new drugs and reduced financial risks.
MORE CENTER NEWS
NCATS-FDA team will develop a Collaborative Use Repurposing Engine (CURE)
Two drugs already on the market may be potential treatments for multiple sclerosis.
IN THE SPOTLIGHT
On April 2, 2015, NCATS released two funding opportunities through the Clinical and Translational Science Awards (CTSA) program. These awards will support innovative investigations among three or more CTSA hubs to improve research methods at any step of the translational process.